The unintended consequences of the 340B safety-net drug discount program.
作者信息
Thomas Samuel, Schulman Kevin
机构信息
Department of Medicine and Population Health, Stanford University School of Medicine, Stanford, California.
Intermountain Healthcare Delivery Institute, Intermountain Healthcare, Murray, Utah.
出版信息
Health Serv Res. 2020 Apr;55(2):153-156. doi: 10.1111/1475-6773.13281. Epub 2020 Mar 1.
Abstract
摘要
相似文献
1
The unintended consequences of the 340B safety-net drug discount program.
Health Serv Res. 2020 Apr;55(2):153-156. doi: 10.1111/1475-6773.13281. Epub 2020 Mar 1.
2
The 340B drug discount program: hospitals generate profits by expanding to reach more affluent communities.
Health Aff (Millwood). 2014 Oct;33(10):1786-92. doi: 10.1377/hlthaff.2014.0540.
3
Relationship between initiation of 340B participation and hospital safety-net engagement.
Health Serv Res. 2020 Apr;55(2):157-169. doi: 10.1111/1475-6773.13278.
4
The 340B discount program: outpatient prescription dispensing patterns through contract pharmacies in 2012.
Health Aff (Millwood). 2014 Nov;33(11):2012-7. doi: 10.1377/hlthaff.2014.0833.
5
Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program.
PLoS One. 2019 Mar 14;14(3):e0213745. doi: 10.1371/journal.pone.0213745. eCollection 2019.
6
Comprehensive Legislative Reform to Protect the Integrity of the 340B Drug Discount Program.
Food Drug Law J. 2015;70(4):481-99, i.
7
Revenues and Profits From Medicare Patients in Hospitals Participating in the 340B Drug Discount Program, 2013-2016.
JAMA Netw Open. 2019 Oct 2;2(10):e1914141. doi: 10.1001/jamanetworkopen.2019.14141.
8
Role of the 340B Drug Discount Program in Recent Cancer Care Trends.
J Oncol Pract. 2015 Jul;11(4):303-7. doi: 10.1200/JOP.2014.002139. Epub 2015 Jun 2.
9
Impact of the 340B Pharmacy Program on Services and Supports for Persons Served by Hemophilia Treatment Centers in the United States.
Matern Child Health J. 2018 Sep;22(9):1240-1246. doi: 10.1007/s10995-018-2545-7.
10
The impact of specialty pharmaceuticals as drivers of health care costs.
Health Aff (Millwood). 2014 Oct;33(10):1714-20. doi: 10.1377/hlthaff.2014.0558.
引用本文的文献
1
The Association of 340B Program Drug Margins with Covered Entity Characteristics.
Inquiry. 2025 Jan-Dec;62:469580251324051. doi: 10.1177/00469580251324051. Epub 2025 Mar 23.
2
Outpatient chemotherapy drug costs and expensive chemotherapy drug use in 340B and Non-340B hospitals: an observational study.
BMC Health Serv Res. 2025 Jan 28;25(1):157. doi: 10.1186/s12913-024-12188-1.
3
US Hospital Service Availability and New 340B Program Participation.
JAMA Health Forum. 2024 May 3;5(5):e240833. doi: 10.1001/jamahealthforum.2024.0833.
4
Community Health Center 340B Program: A Qualitative Study of the Experiences of Patients with Diabetes.
Innov Pharm. 2023 Nov 9;14(3). doi: 10.24926/iip.v14i3.5445. eCollection 2023.
5
Outcomes of the 340B Drug Pricing Program: A Scoping Review.
JAMA Health Forum. 2023 Nov 3;4(11):e233716. doi: 10.1001/jamahealthforum.2023.3716.
6
Sources of Clinician Burnout in Providing Care for Underserved Patients in a Safety-Net Healthcare System.
J Gen Intern Med. 2023 May;38(6):1468-1475. doi: 10.1007/s11606-022-07896-5. Epub 2022 Nov 14.
7
Association of Beneficiary-Level Risk Factors and Hospital-Level Characteristics With Medicare Part B Drug Spending Differences Between 340B and Non-340B Hospitals.
JAMA Netw Open. 2022 Feb 1;5(2):e220045. doi: 10.1001/jamanetworkopen.2022.0045.
8
Spending For Orphan Indications Among Top-Selling Orphan Drugs Approved To Treat Common Diseases.
Health Aff (Millwood). 2021 Mar;40(3):453-460. doi: 10.1377/hlthaff.2020.01442.
本文引用的文献
1
Prices Paid to Hospitals by Private Health Plans Are High Relative to Medicare and Vary Widely: Findings from an Employer-Led Transparency Initiative.
Rand Health Q. 2021 Aug 16;9(2):5. eCollection 2021 Aug.
2
Relationship between initiation of 340B participation and hospital safety-net engagement.
Health Serv Res. 2020 Apr;55(2):157-169. doi: 10.1111/1475-6773.13278.
3
Revenues and Profits From Medicare Patients in Hospitals Participating in the 340B Drug Discount Program, 2013-2016.
JAMA Netw Open. 2019 Oct 2;2(10):e1914141. doi: 10.1001/jamanetworkopen.2019.14141.
4
Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
JAMA Netw Open. 2019 Jul 3;2(7):e196541. doi: 10.1001/jamanetworkopen.2019.6541.
5
Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program.
PLoS One. 2019 Mar 14;14(3):e0213745. doi: 10.1371/journal.pone.0213745. eCollection 2019.
6
Consequences of the 340B Drug Pricing Program.
N Engl J Med. 2018 Feb 8;378(6):539-548. doi: 10.1056/NEJMsa1706475. Epub 2018 Jan 24.
7
Impact of the 340B Drug Pricing Program on Cancer Care Site and Spending in Medicare.
Health Serv Res. 2018 Oct;53(5):3528-3548. doi: 10.1111/1475-6773.12823. Epub 2018 Jan 22.
8
Trends in hospital-physician integration in medical oncology.
Am J Manag Care. 2017 Oct;23(10):624-627.
9
US Spending on Personal Health Care and Public Health, 1996-2013.
JAMA. 2016 Dec 27;316(24):2627-2646. doi: 10.1001/jama.2016.16885.
10
The 340B drug discount program: hospitals generate profits by expanding to reach more affluent communities.
Health Aff (Millwood). 2014 Oct;33(10):1786-92. doi: 10.1377/hlthaff.2014.0540.
Zotero 插件